
Fifty-Six Years of Prohibition, Two Hours of Treatment: Psychedelic Therapy Is Attracting Billions From Big Pharma
Last week, Eli Lilly (LLY) announced that it would buy a development-stage psychedelics biopharma, AtaiBeckley, for roughly $2.8 billion in cash now, and a potential $1 billion more if Atai meets development and regulatory milestones.




